Gossamer Bio, Inc. (GOSS): Shareholders' Equity
-$122.76M
As of 2025-12-31
-$94.03M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$122.76M | n/m | 2026-03-17, Balance as of period end |
| 2024-12-31 | $29.49M | -53.0% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $62.77M | +419.7% | 2026-03-17, Balance as of period end |
| 2022-12-31 | $12.08M | -90.1% | 2025-03-13, Balance as of period end |
| 2021-12-31 | $121.46M | -62.1% | 2024-03-05, Balance as of period end |
| 2020-12-31 | $320.68M | -9.0% | 2023-03-17, Balance as of period end |
| 2019-12-31 | $352.49M | n/m | 2022-03-03, Balance as of period end |
| 2018-12-31 | -$120.07M | n/m | 2021-02-26, Balance as of period end |
| 2017-12-31 | -$6.86M | n/a | 2020-03-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $614.71M | -9.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $381.93M | -9.1% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $654.31M | +107.5% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$33.66M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $24.88M | +8.9% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $17.67M | -13.0% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $35.27M | +100.4% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗